MicroRNAs in cancer drug resistance: Basic evidence and clinical applications

  title={MicroRNAs in cancer drug resistance: Basic evidence and clinical applications},
  author={Mehri Ghasabi and Behzad Mansoori and Ali Mohammadi and Pascal H. G. Duijf and Navid Shomali and Naghmeh Shirafkan and Ahad Mokhtarzadeh and Behzad Baradaran},
  journal={Journal of Cellular Physiology},
  pages={2152 - 2168}
Development of drug resistance has considerably limited the efficacy of cancer treatments, including chemotherapy and targeted therapies. Hence, understanding the molecular mechanisms underpinning the innate or the acquired resistance to these therapies is critical to improve drug efficiency and clinical outcomes. Several studies have implicated microRNAs (miRNA) in this process. MiRNAs repress gene expression by specific binding to complementary sequences in the 3' region of target messenger… 
Advances in the discovery of microRNA-based anticancer therapeutics: latest tools and developments
This review summarizes the various strategies that have been applied to correct the dysregulated miRNA in cancer cells and suggests combination of miRNA therapeutics with other anticancer treatment modalities could provide a synergistic effect, thus allowing the use of lower dose, minimizing off-target effects, and improving the overall safety profile in cancer patients.
Recent developments in targeting genes and pathways by RNAi‐based approaches in colorectal cancer
This review underline the documented benefits of small interfering RNAs and short hairpin RNAs to target genes and signaling pathways related to CRC tumorigenesis and addresses the synergistic effects of RNAi‐mediated gene knockdown and inhibitors/chemotherapy agents to increase the sensitivity of CRC cells to common therapies.
The Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer
To support the discovery of effective diagnostic or therapeutic options using oligonucleotide-based strategies, in the absence of satisfactory therapies for long-term survival and the increasing trend of diseases, this work summarizes the current clinical trials of oligon nucleotide therapeutics for pancreatic cancer patients, with underlying preclinical and scientific data.
Tumor suppressor microRNAs in lung cancer: An insight to signaling pathways and drug resistance
MicroRNAs can be beneficial in combination therapy with other drugs and chemotherapeutic agents for LC and positive or negative effects on drug resistance of LC are directly affected by microRNAs and their target genes.
Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer
To support the discovery of effective diagnostic or therapeutic options by using oligonucleotide-based strategies in the absence of satisfactory therapies for long-term survival and the rising trend of diseases, the current clinical trials of oligon nucleotide therapeutics for pancreatic cancer patients with underlying preclinical or scientific data are summarized.
Curcumin effect on cancer cells' multidrug resistance: An update
Curcumin is suggested as a potent chemosensitizer in cancers because it has been demonstrated that curcumin regulates signaling pathways in cancer cells, reduces the expression of proteins related to drug resistance, and increases the performance of antitumor drugs at various levels.
CD133: An emerging prognostic factor and therapeutic target in colorectal cancer
This review aims to gather the old and most recent data on the prognostic and therapeutic values of CD133 and CD133‐targeted therapies in CRC.
MicroRNA-143 Sensitizes Cervical Cancer Cells to Cisplatin: a Promising Anticancer Combination Therapy
Cisplatin-based chemotherapy is commonly used for cervical cancer treatment. However, the development of chemoresistance is considered the main obstacle to the effectiveness of this therapeutic
The MicroRNA-Based Strategies to Combat Cancer Chemoresistance via Regulating Autophagy
This review focuses on the dual roles of miRNA-mediated autophagy in facilitating or combating chemoresistance, aiming to shed lights on the potential role of miRNAs as targets to overcomeChemoresistance.


The Different Mechanisms of Cancer Drug Resistance: A Brief Review
The mechanisms of cancer drug resistance are outlined and in following, the treatment failures by common chemotherapy agents in the different type of cancers are outlined.
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy
Some of the most important advances in the comprehension of the tumor cell-autonomous and tumor microenvironment-related molecular mechanisms responsible for the resistance of pancreatic cancer to the proapoptotic activity of the classic chemotherapeutic agents and to the most novel anti-angiogenic drugs are discussed.
The role of microRNA in resistance to breast cancer therapy
The role of dysregulated miRNAs in breast cancer that are linked to resistance against chemo‐, radiation, hormone, and targeted therapies is reviewed and the role of miRN as oncogenes or tumor‐suppressor genes is briefly discussed.
Molecular mechanisms for tumour resistance to chemotherapy
This review highlights the current knowledge of the role of altered drug metabolism and transport and deregulation of apoptosis and autophagy in the development of tumour chemoresistance and indicates that deregulation of programmed cell death including apoptotic death is also an important mechanism for tumour resistance to anticancer drugs.
RNA interference and its role in cancer therapy.
The evidence from these studies indicates that RNAi application for targeting functional carcinogenic molecules, tumor resistance to chemotherapy and radiotherapy is required in today's cancer treatment.
Mechanisms of Drug Resistance in Cancer: The Role of Extracellular Vesicles
Drug resistance remains a major barrier to the successful treatment of cancer. The mechanisms by which therapeutic resistance arises are multifactorial. Recent evidence has shown that extracellular
Resistance to Trastuzumab in Breast Cancer
Proposed trastuzumab mode of action as well as proposed mechanisms for resistance are discussed, which will provide insight on how best to treat HER2-overexpressing breast cancer.
Targeted therapy in cancer
  • A. Tsimberidou
  • Medicine, Biology
    Cancer Chemotherapy and Pharmacology
  • 2015
The application of discoveries in cancer biology in clinic holds the promise to improve the clinical outcomes in a large scale of patients with cancer and will expedite the development of anticancer drugs and will accelerate the implementation of precision medicine.
Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer*
It is demonstrated that miR-21 expression was up-regulated and its function was elevated in HER2+ BT474, SKBR3, and MDA-MB-453 breast cancer cells that are induced to acquire trastuzumab resistance by long-term exposure to the antibody, whereas protein expression of the PTEN gene, a miR -21 target, was reduced.